Analysts See $-0.25 EPS for Bavarian Nordic A/S (BVNRY)

May 18, 2018 - By Margarite Burden

Bavarian Nordic A/S (OTCMKTS:BVNRY) Logo

Analysts expect Bavarian Nordic A/S (OTCMKTS:BVNRY) to report $-0.25 EPS on May, 24 before the open.They anticipate $0.24 EPS change or 2,400.00 % from last quarter’s $-0.01 EPS. After having $-0.31 EPS previously, Bavarian Nordic A/S’s analysts see -19.35 % EPS growth. It closed at $9.91 lastly. It is down 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

Bavarian Nordic A/S, a biotechnology company, develops, makes, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company has market cap of $960.01 million. The firm markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It has a 31.66 P/E ratio. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: